


ZK824190

## Chemical Properties

CAS No. : 2254001-81-3  
 Formula: C<sub>22</sub>H<sub>20</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub>  
 Molecular Weight: 414.4  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	ZK824190 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA), with IC <sub>50</sub> values of 237 nM for uPA, 1600 nM for tPA, and 1850 nM for Plasmin.
Targets(IC <sub>50</sub> )	PAI-1, Serine Protease
In vivo	In rats with experimental autoimmune encephalomyelitis (EAE) model, ZK824190 (2? mg/kg; p.o.) exhibited a relatively high oral availability(F?=75%; C <sub>max</sub> =0.64?g/mL and AUC?=2.2?h*g/mL) and a moderate half time of 2.8 h[1].

## Solubility Information

Solubility	DMSO: 12 mg/mL (28.96 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.83 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.4131 mL	12.0656 mL	24.1313 mL
5 mM	0.4826 mL	2.4131 mL	4.8263 mL
10 mM	0.2413 mL	1.2066 mL	2.4131 mL
50 mM	0.0483 mL	0.2413 mL	0.4826 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. *Bioorg Med Chem Lett.* 2018 Nov 1;28(20):3372-3375.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481